However, cannabinoid receptor type 2 (CB2) agonists, as it is the case for A-796260 (Yao et al. 2008), have been associated with liver diseases such as obesity-associated inflammation and insulin resistance (Sherpa et al. 2015). Here, CNR2 is linked to liver disorder.